SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access

European Organisation for Research and Treatment of Cancer (EORTC)

Status: Enrolling

Conditions: All Tumor Types

Treatments: Genetic: RP-1920 BioRadon; Genetic: RP-1828 IMMUcan; Genetic: RP-1843 Arcagen; Genetic: RP-1759 AYA/TYA

Study type: Observational

Funder types: NETWORK

Identifiers

NCT02834884

EORTC-1553

Details and patient eligibility

About

SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.

Full description

Patients are recruited in the platform for the research purpose of 4 downstream projects. For more information, please have a look at the "Groups and cohorts" section.

Enrollment: 4,975 estimated patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Patients with pathologically confirmed selected tumor types (at site or centrally);
• Mandatory availability of adequate human biological material (HBM);
• Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements;
• Age ≥ 12 years;
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
• Written informed consent according to applicable legal and ethical requirements;

Trial design

4,975 participants in 4 patient groups

RP-1828 IMMUcan (CLOSED for recruitment since August 2024)

Description:

The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary

Treatment:

Genetic: RP-1828 IMMUcan

RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)

Description:

The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS

Treatment:

Genetic: RP-1759 AYA/TYA

RP-1843 Arcagen (CLOSED for recruitment since November 2022)

Description:

This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population. Tumor types: all 10 EURACAN domains

Treatment:

Genetic: RP-1843 Arcagen

RP-1920 BioRadon

Description:

The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon). Tumor type: Thorax

Treatment:

Genetic: RP-1920 BioRadon